Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Optimization of liganded polyethylenimine polyethylene glycol vector for nucleic acid delivery.

Joubran S, Zigler M, Pessah N, Klein S, Shir A, Edinger N, Sagalov A, Razvag Y, Reches M, Levitzki A.

Bioconjug Chem. 2014 Sep 17;25(9):1644-54. doi: 10.1021/bc500252a. Epub 2014 Aug 14.

PMID:
25121341
2.

Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid.

Pessah N, Yagen B, Hen N, Shimshoni JA, Wlodarczyk B, Finnell RH, Bialer M.

Epilepsy Behav. 2011 Nov;22(3):461-8. doi: 10.1016/j.yebeh.2011.08.026. Epub 2011 Sep 29.

PMID:
21959082
3.

Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid.

Pessah N, Kaufmann D, Yagen B, Hen N, Wlodarczyk B, Finnell RH, Bialer M.

Epilepsia. 2010 Oct;51(10):1944-53. doi: 10.1111/j.1528-1167.2010.02684.x.

4.

Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid.

Pessah N, Bialer M, Wlodarczyk B, Finnell RH, Yagen B.

J Med Chem. 2009 Apr 23;52(8):2233-42. doi: 10.1021/jm900017f.

PMID:
19296679
5.

Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid.

Shimshoni JA, Yagen B, Pessah N, Wlodarczyk B, Finnell RH, Bialer M.

Epilepsia. 2008 Jul;49(7):1202-12. doi: 10.1111/j.1528-1167.2008.01624.x.

6.

The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior.

Shimshoni JA, Dalton EC, Jenkins A, Eyal S, Ewan K, Williams RS, Pessah N, Yagen B, Harwood AJ, Bialer M.

Mol Pharmacol. 2007 Mar;71(3):884-92. Epub 2006 Dec 13.

PMID:
17167030
7.

Chemical adaptor systems.

Shabat D, Amir RJ, Gopin A, Pessah N, Shamis M.

Chemistry. 2004 Jun 7;10(11):2626-34. Review.

PMID:
15195294
8.

Bioactivation of carbamate-based 20(S)-camptothecin prodrugs.

Pessah N, Reznik M, Shamis M, Yantiri F, Xin H, Bowdish K, Shomron N, Ast G, Shabat D.

Bioorg Med Chem. 2004 Apr 15;12(8):1859-66.

PMID:
15051055
9.

Self-immolative dendrimers.

Amir RJ, Pessah N, Shamis M, Shabat D.

Angew Chem Int Ed Engl. 2003 Sep 29;42(37):4494-9. No abstract available.

PMID:
14520747
10.

A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.

Gopin A, Pessah N, Shamis M, Rader C, Shabat D.

Angew Chem Int Ed Engl. 2003 Jan 20;42(3):327-32. No abstract available.

PMID:
12548691
11.

Lack of effect of carbonic anhydrase inhibition on direct measurements of endolymph bicarbonate.

Isaacs JH Jr, Pessah N, Merwin GE, Maren TH.

Ann Otol Rhinol Laryngol. 1989 Mar;98(3):209-12.

PMID:
2493763
13.

Enhancement of the ocular hypotensive effect of acetazolamide by diflunisal.

Yablonski ME, Maren TH, Hayashi M, Naveh N, Potash SD, Pessah N.

Am J Ophthalmol. 1988 Sep 15;106(3):332-6.

PMID:
3048109
15.

On the use of ketamine in ocular pharmacological studies.

Bar-Ilan A, Pessah NI.

J Ocul Pharmacol. 1986 Fall;2(4):335-44.

PMID:
3503118
16.

Ocular penetration and hypotensive activity of the topically applied carbonic anhydrase inhibitor L-645,151.

Bar-Ilan A, Pessah NI, Maren TH.

J Ocul Pharmacol. 1986 Spring;2(2):109-20.

PMID:
3503100
17.

The effects of carbonic anhydrase inhibitors on aqueous humor chemistry and dynamics.

Bar-Ilan A, Pessah NI, Maren TH.

Invest Ophthalmol Vis Sci. 1984 Oct;25(10):1198-205.

PMID:
6434487
18.

The carbon dioxide hydration activity of skeletal muscle carbonic anhydrase. Inhibition by sulfonamides and anions.

Sanyal G, Swenson ER, Pessah NI, Maren TH.

Mol Pharmacol. 1982 Jul;22(1):211-20. No abstract available.

PMID:
6811858
19.

Kinetics and inhibition of membrane-bound carbonic anhydrase from canine renal cortex.

Sanyal G, Pessah NI, Maren TH.

Biochim Biophys Acta. 1981 Jan 15;657(1):128-37.

PMID:
7213743
20.
21.

Transport of organic ions in renal cortical luminal and antiluminal membrane vesicles.

Kinsella JL, Holohan PD, Pessah NI, Ross CR.

J Pharmacol Exp Ther. 1979 Jun;209(3):443-50.

PMID:
155742
22.

Isolation of luminal and antiluminal membranes from dog kidney cortex.

Kinsella JL, Holohan PD, Pessah NI, Ross CR.

Biochim Biophys Acta. 1979 Apr 19;552(3):468-77.

PMID:
221018
23.

The purification of an organic cation-specific binding protein from dog kidney.

Holohan PD, Pessah NI, Warkentin D, Ross CR.

Mol Pharmacol. 1976 May;12(3):494-503. No abstract available.

PMID:
132605
24.

Binding of N1-methylnicotinamide and p-aminohippuric acid to a particulate fraction from dog kidney.

Holohan PD, Pessah NI, Ross CR.

J Pharmacol Exp Ther. 1975 Oct;195(1):22-33.

PMID:
241840
25.

Reversible inhibition of (Na+ + K+)-ATPase with a cardiac glycoside.

Ross CR, Pessah NI.

Eur J Pharmacol. 1975 Aug;33(1):223-6.

PMID:
126168
26.

The relation of changes in sodium transport to protein-bound disulfide and sulfhydryl groups in the toad bladder epithelium.

Farah A, Yamodis ND, Pessah N.

J Pharmacol Exp Ther. 1969 Nov;170(1):132-44. No abstract available.

PMID:
4310841
27.

Attempts to label the renal carrier for organic bases with dibenamine.

Ross CR, Pessah NI, Farah AE.

J Pharmacol Exp Ther. 1969 Jun;167(2):235-42. No abstract available.

PMID:
4239631
28.

Inhibitory effects of beta-haloalkylamines on the renal transport of N-methylnicotinamide.

Ross CR, Pessah NI, Farah A.

J Pharmacol Exp Ther. 1968 Apr;160(2):375-80. No abstract available.

PMID:
4231364
29.

Studies of uptake and runout of p-aminohippurate and N-methylnicotinamide in dog renal slices.

Ross CR, Pessah NI, Farah A.

J Pharmacol Exp Ther. 1968 Apr;160(2):381-6. No abstract available.

PMID:
4231032

Supplemental Content

Loading ...
Support Center